News in brief

US FDA gives CordenPharma Latina's Italian plant the all clear

Google Maps

CordenPharma Latina has resolved the problems that earned its API and injectable drug facility in Sermoneta, Italy a warning letter from the US FDA last year.

The US regulator gave the plant a clean bill of health in a closeout letter this month, explaining that: “Based on our evaluation, it appears that you have addressed the violations and or deviations.”

The Sermoneta facility – which was previously owned by Bristol Myers - makes oral and sterile liquid dosage forms antibiotics, including cephalosporin and penicillins. It was also cleared to manufacture freeze-dried cancer drugs for clinical trials in July 2015.

CordenPharma – which is owned by Germany-based International Chemical Investors Group (ICIG) – said addressing the issues – which were detailed in a warning letter in May last year – had involved a “holistic and systematic approach.”

The firm declined to comment further when contacted by in-Pharmatechnologist.com.

Related News

CordenPharma facility in Sermoneta, Italy

US FDA warns CordenPharma about Italian antibiotic API and cancer injectables plant

Acasti's CaPre is sourced from krill. Image: iStock/pilipenkoD

Acasti and CordenPharma look to continuous production for omega-3 drug

ICIG Belgian Peptide Firm to Boost API business

CordenPharma Owner Buys Belgian Peptide Firm to Boost API business

CordenPharma certified to handle HPAPIs at Colorado plant

CordenPharma certified to handle HPAPIs under SafeBridge safety programme

Related Products

See more related products